EMA Strengthens Regulations for Gender-Specific Clinical Data to Promote the Development of Women's Medicines, Including Astellas' 'Veoza'
Shift in Regulatory Paradigm Towards Women's Health and its Background
The European Medicines Agency (EMA) has launched a series of initiatives to integrate women's health as a core element in drug development and regulation. This aims to fundamentally change the criteria for evaluating the efficacy and safety of medicines for women, who have longer lifespans but shorter periods of good health compared to men. A key objective is to address the data gap that has arisen due to low participation rates of women in clinical trials and insufficient sex-disaggregated analysis. This shift in the regulatory paradigm is expected to further stimulate the development of innovative drugs that consider women's specific physiological characteristics from the early stages of candidate substance discovery.
Mandatory Sex-Disaggregated Analysis and Challenges for the Pharmaceutical Industry
Pharmaceutical companies will now face stronger regulatory pressure to incorporate sex-related factors and physiological differences into the design of clinical trials. In the past, subtle differences in pharmacokinetics (PK) and pharmacodynamics (PD) between sexes were often overlooked in clinical statistics, but now, thorough demonstration of sex-specific data is required. This will make the process of recruiting clinical trial subjects and monitoring safety even more complex, potentially increasing the cost of drug development in the short term. However, by proactively preventing sex-specific adverse effects and clearly demonstrating therapeutic efficacy, it is expected to significantly improve the overall success rate of clinical trials in the long term.
'Veoza' and 'Fylrevy' Demonstrate the Potential of the Women's Health Market
The global market has already seen Astellas Pharma's non-hormonal menopause treatment, Veoza (fezolinetant), and Gedeon Richter's hormone replacement therapy, Fylrevy, successfully establish themselves, demonstrating the enormous potential of the women's health sector. The global women's health market is estimated at approximately $53.5 billion in 2025 and is projected to grow rapidly to about $57.2 billion in 2026. The EMA's initiative is expected to serve as a strong catalyst for the development of pipelines in unexplored disease areas, such as endometriosis and preeclampsia, where there has been a lack of adequate treatment options.
Plans to Establish Global Standards Through a Workshop in September
The EMA plans to hold a women's health workshop for two days, from September 28th to 29th, 2026, to establish a detailed roadmap for follow-up guidelines. Emer Cooke, EMA Executive Director, emphasized that the agency will actively lead the development of a drug development environment that is precisely tailored to the physical characteristics of women. The sex-specific data guidelines to be established at this conference will become a new benchmark that global bio-companies targeting the European market must comply with. Therefore, companies should proactively accumulate sex-comparative analysis data for their pipelines to minimize the risk of approval delays.
The EMA's strengthening of women's health clinical regulations is expected to have a short-term impact of significantly raising the approval hurdles for new drug pipelines in the global women's health market, which is projected to reach $57.2 billion in 2026. Researchers will need to design sex-disaggregated analyses from Phase 1 clinical trials, making it essential to demonstrate a comparison of sex-specific efficacy compared to already approved drugs such as Astellas Pharma's 'Veoza' and Gedeon Richter's 'Fylrevy'. From the perspective of industry professionals, the increased complexity of Phase 3 trial designs and the longer subject recruitment periods could lead to increased development costs in the medium to long term. However, from an investor's perspective, bio-companies that proactively accumulate sex-differentiated data and successfully pass the final approval hurdles are expected to establish barriers to entry and secure long-term exclusivity.